Research data show that in diabetes patients who had failure, the use of SGLT2 inhibitors reduces hospitalizations and all-cause mortality due to heart failure compared to other hypoglycemic drugs [4,5]. The gene discussed is SLC5A2; the disease is diabetes mellitus.